At 12 months, 60% patients on the 0.3 mg/kg dose maintained a response. The trial’s secondary endpoints were duration of response (DoR), the percent reduction in daily steroids dose, organ-specific response rates, and validated quality-of-life (QoL) assessments. There are not yet conclusive data on median DoR, however, 55% of patients in the 0.3 mg/kg arm experienced a clinically meaningful improvement on the QoL assessment. “These findings further support that axatilimab has the potential to provide a clinically meaningful response for patients suffering from this morbid condition." ReferenceSyndax And Incyte Announce Positive Topline Results From The Pivotal AGAVE-201 Trial Of Axatilimab In Chronic Graft-Versus-Host Disease.

Source: Washington Post July 25, 2023 13:09 UTC